Evidence map›Paper›PMID 25514610›Full record

ArticlePloS one2014

Frequency of COL4A3/COL4A4 mutations amongst families segregating glomerular microscopic hematuria and evidence for activation of the unfolded protein response. Focal and segmental glomerulosclerosis is a frequent development during ageing.

Louiza Papazachariou, Panayiota Demosthenous, Myrtani Pieri, Gregory Papagregoriou, Isavella Savva, Christoforos Stavrou, Michael Zavros, Yiannis Athanasiou, Kyriakos Ioannou, Charalambos Patsias and 21 more

Abstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Observational
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Louiza PapazachariouMolecular Medicine Research Center and Laboratory of Molecular and Medical Genetics, University of Cyprus, Nicosia, Cyprus.
Panayiota DemosthenousMolecular Medicine Research Center and Laboratory of Molecular and Medical Genetics, University of Cyprus, Nicosia, Cyprus.
Myrtani PieriMolecular Medicine Research Center and Laboratory of Molecular and Medical Genetics, University of Cyprus, Nicosia, Cyprus.
Gregory PapagregoriouMolecular Medicine Research Center and Laboratory of Molecular and Medical Genetics, University of Cyprus, Nicosia, Cyprus.
Isavella SavvaMolecular Medicine Research Center and Laboratory of Molecular and Medical Genetics, University of Cyprus, Nicosia, Cyprus.
Christoforos StavrouDepartment of Nephrology, Evangelismos Hospital, Pafos, Cyprus.
Michael ZavrosDepartment of Nephrology, Nicosia General Hospital, Nicosia, Cyprus.
Yiannis AthanasiouDepartment of Nephrology, Nicosia General Hospital, Nicosia, Cyprus.
Kyriakos IoannouDepartment of Nephrology, Nicosia General Hospital, Nicosia, Cyprus.
Charalambos PatsiasDepartment of Nephrology, Nicosia General Hospital, Nicosia, Cyprus.
Alexia PanagidesDepartment of Nephrology, Nicosia General Hospital, Nicosia, Cyprus.
Costas PotamitisDepartment of Nephrology, Nicosia General Hospital, Nicosia, Cyprus.
Kyproula DemetriouDepartment of Nephrology, Nicosia General Hospital, Nicosia, Cyprus.
Marios PrikisDepartment of Nephrology, Nicosia General Hospital, Nicosia, Cyprus.
Michael HadjigavrielDepartment of Nephrology, Larnaca General Hospital, Larnaca, Cyprus.
Maria KkolouDepartment of Nephrology, Larnaca General Hospital, Larnaca, Cyprus.
Panayiota LoukaidouDepartment of Nephrology, Larnaca General Hospital, Larnaca, Cyprus.
Androulla PastelliDepartment of Nephrology, Larnaca General Hospital, Larnaca, Cyprus.
Aristos MichaelDepartment of Nephrology, Limassol General Hospital, Limassol, Cyprus.
Akis LazarouDepartment of Nephrology, Limassol General Hospital, Limassol, Cyprus.
Maria ArsaliDepartment of Nephrology, Limassol General Hospital, Limassol, Cyprus.
Loukas DamianouDepartment of Nephrology, Limassol General Hospital, Limassol, Cyprus.
Ioanna GoutziamaniDepartment of Nephrology, Limassol General Hospital, Limassol, Cyprus.
Andreas SoloukidesDepartment of Nephrology, Limassol General Hospital, Limassol, Cyprus.
Lakis YioukasDepartment of Nephrology, Paphos General Hospital, Paphos, Cyprus.
Avraam EliaDepartment of Pediatrics, Archbishop Makarios III Hospital, Nicosia, Cyprus.
Ioanna ZouvaniDepartment of Histopathology, Nicosia General Hospital, Nicosia, Cyprus.
Polycarpos PolycarpouDepartment of Nephrology, Apollonion Private Hospital, Nicosia, Cyprus.
Alkis PieridesDepartment of Nephrology, Hippocrateon Hospital, Nicosia, Cyprus.
Konstantinos VoskaridesMolecular Medicine Research Center and Laboratory of Molecular and Medical Genetics, University of Cyprus, Nicosia, Cyprus.
Constantinos DeltasMolecular Medicine Research Center and Laboratory of Molecular and Medical Genetics, University of Cyprus, Nicosia, Cyprus.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Familial glomerular hematuria(s) comprise a genetically heterogeneous group of conditions which include Alport Syndrome (AS) and thin basement membrane nephropathy (TBMN). Here we investigated 57 Greek-Cypriot families presenting glomerular microscopic hematuria (GMH), with or without proteinuria or chronic kidney function decline, but excluded classical AS. We specifically searched the COL4A3/A4 genes and identified 8 heterozygous mutations in 16 families (28,1%). Eight non-related families featured the founder mutation COL4A3-p.(G1334E). Renal biopsies from 8 patients showed TBMN and focal segmental glomerulosclerosis (FSGS). Ten patients (11.5%) reached end-stage kidney disease (ESKD) at ages ranging from 37-69-yo (mean 50,1-yo). Next generation sequencing of the patients who progressed to ESKD failed to reveal a second mutation in any of the COL4A3/A4/A5 genes, supporting that true heterozygosity for COL4A3/A4 mutations predisposes to CRF/ESKD. Although this could be viewed as a milder and late-onset form of autosomal dominant AS, we had no evidence of ultrastructural features or extrarenal manifestations that would justify this diagnosis. Functional studies in cultured podocytes transfected with wild type or mutant COL4A3 chains showed retention of mutant collagens and differential activation of the unfolded protein response (UPR) cascade. This signifies the potential role of the UPR cascade in modulating the final phenotype in patients with collagen IV nephropathies.

Indexed as

AdultAgedAgingAutoantigensBase SequenceCell LineCollagen Type IVFemaleGlomerular Basement MembraneGlomerulosclerosis, Focal SegmentalHematuriaHigh-Throughput Nucleotide SequencingHumansKidney Failure, ChronicMaleMiddle AgedAutoantigensCOL4A4 protein, humanCollagen Type IVtype IV collagen alpha3 chain

Identifiers

PMID25514610
PMCPMC4267773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.